|Bid||7.11 x 2200|
|Ask||7.16 x 900|
|Day's Range||7.08 - 7.44|
|52 Week Range||3.60 - 9.76|
|Beta (3Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD) this week at the Parent Project Muscular Dystrophy (PPMD) 25th Annual Conference. Screening is ongoing for the randomized, double-blind, placebo-controlled trial in the United States, Canada, Australia, the United Kingdom, Ireland, Sweden, Germany and Israel and making strong progress. Clinical trial sites globally are enrolling quickly and sites in the United Kingdom, Ireland, Sweden, Germany and Israel are at capacity and no longer accepting additional patients.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD). Edasalonexent is a novel NF-kB inhibitor in Phase 3 development for the treatment of DMD. The data were presented at the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy.
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy , at two upcoming meetings: the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and the Parent Project Muscular Dystrophy 25th Annual Conference.
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the ...
-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Enrolling Boys Globally --
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annual Meeting to be held May 4 to May 10, 2019 in Philadelphia, PA. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent, will give an oral presentation titled “Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7 Year-Old Patients with Duchenne Muscular Dystrophy” during the S51 session “Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders” on Thursday, May 9 at 4:25pm ET.
The company will host a conference call at 8:30am ET
Anyone researching Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of...
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the 12th UK Neuromuscular Translational Research Conference and the 2019 Muscular Dystrophy Association ...
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
-- Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys with Duchenne Muscular Dystrophy --
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 8:00am ET at the Westin New York Grand Central Hotel in New York City, NY.
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathizeRead More...